RT Journal Article
SR Electronic
T1 C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy Using [<sup>99m</sup>Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1640
OP 1644
DO 10.2967/jnumed.124.268169
VO 65
IS 10
A1 Enke, Johanna S.
A1 Ritzel, Kathrin
A1 Asbach, Evelyn
A1 Reitsam, Nic G.
A1 Märkl, Bruno
A1 Knösel, Thomas
A1 Brüdgam, Denise
A1 Kircher, Malte
A1 Pfob, Christian H.
A1 Bundschuh, Ralph A.
A1 Rinscheid, Andreas
A1 Nittbaur, Bernd
A1 Wienand, Georgine
A1 Schottelius, Margret
A1 Reincke, Martin
A1 Lapa, Constantin
A1 Dierks, Alexander
YR 2024
UL http://jnm.snmjournals.org/content/65/10/1640.abstract
AB C-X-C motif chemokine receptor 4 (CXCR4)–directed imaging has gained clinical interest in aiding clinical diagnostics in primary aldosteronism (PA). We retrospectively evaluated the feasibility of CXCR4-directed scintigraphy using the novel CXCR-4 ligand [99mTc]Tc-pentixatec in patients with PA. Methods: Six patients (mean age ± SD, 49 ± 15 y) underwent CXCR4-directed scintigraphy (including planar imaging and SPECT/CT) 30, 120, and 240 min after injection of 435 ± 50 MBq of [99mTc]Tc-pentixatec. Adrenal CXCR4 expression was analyzed by calculating lesion-to-contralateral ratios (LCRs). Imaging results were correlated to clinical information. Histopathology and clinical follow-up served as the standard of reference. Results: Three subjects showed lateralization of adrenal tracer accumulation, with a mean maximum lesion-to-contralateral ratio of 1.65 (range, 1.52–1.70), which correlated with morphologic findings on CT. One individual underwent adrenalectomy and presented with complete biochemical and clinical remission at follow-up. Histopathologic workup confirmed unilateral aldosterone-producing adenoma. Conclusion: [99mTc]Tc-pentixatec scintigraphy with SPECT in patients with PA is feasible and might offer a valuable alternative to CXCR4-directed imaging with [68Ga]Ga-pentixafor PET.